The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction
Sodium-glucose cotransporter type 2 (SGLT2) inhibitors are a relatively new class of antihyperglycemic drug with salutary effects on glucose control, body weight, and blood pressure. Emerging evidence now indicates that these drugs may have a beneficial effect on outcomes in heart failure with reduc...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-03-01
|
| Series: | Therapeutic Advances in Cardiovascular Disease |
| Online Access: | https://doi.org/10.1177/17539447211002678 |